Detalhe da pesquisa
1.
A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
Br J Haematol
; 204(3): 871-876, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38016651
2.
A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial.
Br J Haematol
; 200(5): 573-578, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36413792
3.
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
Br J Haematol
; 198(3): 528-534, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35388465
4.
Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.
Blood
; 125(19): 2923-32, 2015 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25805811
5.
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.
Blood
; 125(25): 3878-85, 2015 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25833957
6.
Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients.
Blood Adv
; 5(24): 5621-5625, 2021 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34597366
7.
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
J Clin Oncol
; 39(8): 890-901, 2021 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33356418